ROCKVILLE, Md.--(BUSINESS WIRE)-- 20/20 GeneSystems, Inc. (“20/20”), a developer of innovative diagnostic products for early disease detection and personalized medicine, today announced that it has entered into an agreement with Raritan, N.J., based Ortho-Clinical Diagnostics (“OCD”) to license certain 20/20 intellectual property relating to a blood test for the early detection of lung cancer.
